No Data
No Data
Stocks to Watch: Avadel Pharmaceuticals, Siyata Mobile, Liberty Media
Avadel Sees Narcolepsy Drug Fueling Earnings Growth
Avadel Pharmaceuticals Projects Robust Growth for LUMRYZ
Avadel Pharmaceuticals Preliminary Q4 Net Product Revenue Rises; 2025 Outlook Set; Shares Fall After Hours
Avadel Pharma: Positive Cash Flow in 4Q Ending With About $73M of Cash, Cash Equivalents and Marketable Securities >AVDL
Avadel Pharmaceuticals Sees 2025 LUMRYZ Net Pdt Rev of $240 - $260 M >AVDL
No Data